Candriam S.C.A. Regeneron Pharmaceuticals, Inc. Transaction History

Candriam S.C.A.

$16.3 Billion
Q2 2024

A detailed history of Candriam S.C.A. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 200,708 shares of REGN stock, worth $209 Million. This represents 1.3% of its overall portfolio holdings.

Number of Shares

200,708

Previous 217,771 7.84%

Holding current value

$209 Million

Previous $210 Million 0.64%

% of portfolio

1.3%

Previous 1.36%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	SELL	$883.2 - $1071.19 $15.1 Million - $18.3 Million	-17,063 Reduced 7.84%	200,708 $211 Million
Q1 2024 May 03, 2024	SELL	$902.69 - $993.35 $21.5 Million - $23.7 Million	-23,847 Reduced 9.87%	217,771 $210 Million
Q4 2023 Feb 14, 2024	SELL	$775.18 - $881.7 $37.7 Million - $42.9 Million	-48,692 Reduced 16.77%	241,618 $212 Million
Q3 2023 Nov 13, 2023	SELL	$692.45 - $844.37 $10.6 Million - $12.9 Million	-15,308 Reduced 5.01%	290,310 $239 Million
Q2 2023 Aug 08, 2023	SELL	$700.03 - $830.35 $30.4 Million - $36 Million	-43,370 Reduced 12.43%	305,618 $220 Million
Q1 2023 May 12, 2023	SELL	$680.49 - $826.97 $23.1 Million - $28.1 Million	-33,980 Reduced 8.87%	348,988 $287 Million
Q4 2022 Feb 13, 2023	SELL	$705.89 - $766.39 $13.8 Million - $15 Million	-19,553 Reduced 4.86%	382,968 $276 Million
Q3 2022 Nov 10, 2022	BUY	$573.97 - $724.32 $17.1 Million - $21.5 Million	29,728 Added 7.97%	402,521 $277 Million
Q2 2022 Aug 03, 2022	BUY	$548.35 - $738.84 $1.92 Million - $2.59 Million	3,503 Added 0.95%	372,793 $220 Million
Q1 2022 May 13, 2022	BUY	$595.12 - $698.43 $2.8 Million - $3.29 Million	4,704 Added 1.29%	369,290 $258 Million
Q4 2021 Feb 10, 2022	SELL	$543.48 - $670.97 $13.1 Million - $16.1 Million	-24,057 Reduced 6.19%	364,586 $230 Million
Q3 2021 Nov 09, 2021	SELL	$574.03 - $680.96 $81.3 Million - $96.5 Million	-141,703 Reduced 26.72%	388,643 $235 Million
Q2 2021 Jul 20, 2021	BUY	$472.8 - $558.54 $59.9 Million - $70.8 Million	126,705 Added 31.39%	530,346 $296 Million
Q1 2021 Apr 29, 2021	BUY	$446.73 - $548.2 $1,786 - $2,192	4 Added 0.0%	403,641 $187 Million
Q4 2020 Jan 22, 2021	BUY	$478.3 - $607.98 $38.6 Million - $49 Million	80,601 Added 24.95%	403,637 $195 Million
Q3 2020 Oct 19, 2020	BUY	$544.75 - $658.21 $51.3 Million - $62 Million	94,135 Added 41.12%	323,036 $181 Million
Q2 2020 Jul 23, 2020	SELL	$493.32 - $643.92 $89.9 Million - $117 Million	-182,315 Reduced 44.34%	228,901 $143 Million
Q1 2020 May 26, 2020	BUY	$336.18 - $494.43 $1,680 - $2,472	5 Added 0.0%	411,216 $151 Million
Q4 2019 Jan 21, 2020	SELL	$274.13 - $376.51 $263,987 - $362,579	-963 Reduced 0.23%	411,211 $154,000
Q3 2019 Oct 21, 2019	BUY	$273.46 - $318.39 $7.23 Million - $8.42 Million	26,433 Added 6.85%	412,174 $114,000
Q2 2019 Aug 01, 2019	BUY	$299.6 - $414.82 $11.5 Million - $16 Million	38,470 Added 11.08%	385,741 $120 Million
Q1 2019 May 02, 2019	SELL	$372.08 - $439.57 $775,042 - $915,624	-2,083 Reduced 0.6%	347,271 $143 Million
Q4 2018 Feb 14, 2019	BUY	$335.82 - $403.04 $997,721 - $1.2 Million	2,971 Added 0.86%	349,354 $130 Million
Q3 2018 Nov 07, 2018	BUY	$351.14 - $408.51 $55.4 Million - $64.5 Million	157,800 Added 83.68%	346,383 $140 Million
Q2 2018 Aug 14, 2018	BUY	$284.6 - $344.99 $16.8 Million - $20.3 Million	58,963 Added 45.49%	188,583 $65.1 Million
Q1 2018 May 09, 2018	BUY	$315.82 - $393.78 $2.69 Million - $3.36 Million	8,528 Added 7.04%	129,620 $44.6 Million
Q4 2017 Feb 07, 2018	SELL	$358.63 - $469.95 $3.55 Million - $4.65 Million	-9,900 Reduced 7.56%	121,092 $45.5 Million
Q3 2017 Nov 03, 2017	BUY	$431.38 - $504.0 $56.5 Million - $66 Million	130,992	130,992 $58.6 Million

Others Institutions Holding REGN

# of Institutions

1,463

Shares Held

84.5M

Call Options Held

907K

Put Options Held

1.3M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $112B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account